New York-based cancer giant Bristol Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration has extended the review of its supplemental biologics license application (sBLA) for Reblozyl (luspatercept-aamt).
Bristol Myers is developing the therapy for the treatment of anemia in adults with non-transfusion-dependent beta thalassemia.
The company is working with Merck & Co (NYSE: MRK) on the development of the candidate, following Merck’s acquisition of Acceleron Pharma in November 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze